DoW Arthritis Translational Research Award

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.

Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.

Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Oct 22, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Arthritis Translational Research Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.